Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization

European Heart Journal

Volumn 23, Issue 15, 2002, Pages 1213-1218

  Husted, Steen E ^a   Wallentin, L ^b   Lagerqvist, B ^c   Kontny, F ^d   Stahle E ^c   Swahn, E ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Uppsala Cardiothoracic Center   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulant; CABG; Dalteparin; Extended treatment; Invasive management; Non invasive management; PTCA; Unstable coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; PLACEBO;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STROKE;

EID: 0036700352     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3077     Document Type: Article

References (18)

1. Merlini P, Bauer K, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
2. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L. Low molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79: 491-4.
3. Feldman RL. Coronary thrombosis, coronary spasm and coronary atherosclerosis and speculation on the link between unstable angina and acute myocardial infarction. Am J Cardiol 1987; 59: 1187-90.
4. Verheugt FW. Acute coronary syndromes: Drug treatments. Lancet 1999; 353 (Suppl 2): SII20-3.
5. FRagmin during InStability in Coronary artery disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
6. Klein W, Buchwald A, Hillis SE et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61-8.
7. Theroux P, Waters D, Lam J et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5.
8. Kontny F. Reactivation of the coagulation system: Rationale for long-term antithrombotic treatment. Am J Cardiol 1997; 80 (5A): 55E-60E.
9. Fragmin and fast revascularisation during instability in coronary artery disease (FRISC II) investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-7.
10. Fragmin and fast revascularisation during instability in coronary artery disease (FRISC II) investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective multicentre study. Lancet 1999; 354: 708-15.
11. Wallentin L, Lagerqvist B, Husted S et al. Outcome at I year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. Lancet 2000; 356: 9-16.
12. Task force members. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation. Eur Heart J 2000; 21: 1406-32.
13. Unger F. Cardiac Interventions in Europe 1997: Coronary revascularization procedures and open heart surgery. Cor Europeum 1999; 7: 177-89.
14. Cardiovascular Diseases in Europe, European Registries of Cardiovascular Diseases and Patient Management. Sophia Antipolis, France: European Society of Cardiology, 1999.
15. Wester PO, Nyberg L. Meeting report, PTCA-activity in Sweden. In: 1999: Socialstyrelsen, Sweden, 1999.
16. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62.
17. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
18. Stahle E, Lindahl B. Antithrombotic treatment in patients with unstable coronary artery disease undergoing CABG. Ann Thorac Surg 2001; 71: 1748-56.